Rosa Ferrao - Ventyx Biosciences Senior Affairs
| VTYX Stock | USD 1.41 0.02 1.40% |
Executive
Rosa Ferrao is Senior Affairs of Ventyx Biosciences
| Address | 12790 El Camino Real, San Diego, CA, United States, 92130 |
| Phone | 760 593 4832 |
| Web | https://ventyxbio.com |
Ventyx Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.3348) % which means that it has lost $0.3348 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5427) %, meaning that it created substantial loss on money invested by shareholders. Ventyx Biosciences' management efficiency ratios could be used to measure how well Ventyx Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.51 in 2025. Return On Capital Employed is likely to rise to -0.53 in 2025. At this time, Ventyx Biosciences' Net Tangible Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 38.5 M in 2025, whereas Total Assets are likely to drop slightly above 223.3 M in 2025.Ventyx Biosciences currently holds 10.79 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Ventyx Biosciences has a current ratio of 13.98, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Ventyx Biosciences' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Scott MD | Protagonist Therapeutics | N/A | |
| David Liu | Protagonist Therapeutics | 74 | |
| Hui Lei | Structure Therapeutics American | N/A | |
| Joseph Kelly | Ascendis Pharma AS | 56 | |
| FACP MD | Protagonist Therapeutics | 65 | |
| Bob Gatmaitan | Structure Therapeutics American | N/A | |
| Scott Holmes | Ascendis Pharma AS | N/A | |
| Joshua Bleharski | Ideaya Biosciences | N/A | |
| Colin Love | Replimune Group | 66 | |
| Pamela Esposito | Replimune Group | 50 | |
| Kevin Gray | United Therapeutics | N/A | |
| Richard Shames | Protagonist Therapeutics | 64 | |
| Heba Nowyhed | Arcellx | N/A | |
| Joseph MD | Syndax Pharmaceuticals | N/A | |
| David MD | Immunocore Holdings | 54 | |
| Kathleen MD | Verona Pharma PLC | 67 | |
| Stuart Dorman | Ideaya Biosciences | N/A | |
| Paul MBA | Vaxcyte | 63 | |
| Paul Barsanti | Ideaya Biosciences | N/A | |
| Carolyn Trott | Replimune Group | N/A | |
| Douglas Snyder | Ideaya Biosciences | 61 | |
Management Performance
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.33 |
Ventyx Biosciences Leadership Team
Elected by the shareholders, the Ventyx Biosciences' board of directors comprises two types of representatives: Ventyx Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ventyx. The board's role is to monitor Ventyx Biosciences' management team and ensure that shareholders' interests are well served. Ventyx Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ventyx Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Moore, Chief Officer | ||
| Snehal Naik, Senior Development | ||
| Kye MD, Data Biostatistics | ||
| Sheila MD, Executive Chairperson | ||
| John Nuss, Chief Officer | ||
| Martin MD, Chief Officer | ||
| Kathy Ogilvie, Senior Research | ||
| Prof MD, Pres Officer | ||
| Rosa Ferrao, Senior Affairs | ||
| Raju Mohan, CEO, Founder | ||
| MBA JD, Chief Officer |
Ventyx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ventyx Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | (100.54 M) | ||||
| Shares Outstanding | 71.13 M | ||||
| Shares Owned By Insiders | 4.46 % | ||||
| Shares Owned By Institutions | 86.92 % | ||||
| Number Of Shares Shorted | 6.62 M | ||||
| Price To Book | 0.42 X | ||||
| EBITDA | (148.45 M) | ||||
| Net Income | (135.12 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Ventyx Stock Analysis
When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.